Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease

Area of Science:

• Oncology
• Drug Development
• Biochemistry

Background:

• Achieving selective cancer cell eradication while sparing healthy tissues is a critical challenge in cancer therapy.
• There is an urgent need for highly selective anticancer drugs to improve treatment efficacy and reduce side effects.

Purpose of the Study:

• To develop and validate a novel prodrug strategy for selective cancer therapy.
• To leverage the unique enzymatic environment of cancer cells for targeted drug activation.

Main Methods:

• A prodrug was synthesized by coupling an acetylated lysine group to puromycin, a cytotoxic agent.
• The prodrug's activation mechanism was investigated, involving sequential cleavage by histone deacetylase (HDAC) and cathepsin L (CTSL).
• The efficacy of the prodrug was evaluated in human cancer cell lines and in vivo xenograft models.

Main Results:

• The prodrug demonstrated selective activation and cytotoxicity in cancer cell lines with elevated HDAC and CTSL activities.
• In vivo studies showed significant tumor growth inhibition in mice bearing human cancer xenografts treated with the prodrug.
• The strategy confirmed cancer-selective cleavage of the masking group, leading to the liberation of puromycin.

Conclusions:

• The developed prodrug strategy offers a promising approach for next-generation anticancer drug development.
• This method enables selective cancer cell killing by exploiting increased HDAC and CTSL activities in malignant cells.
• The prodrug strategy has the potential for broad applicability to various cytotoxic agents for enhanced cancer therapy.